Parameters predicting [
Biochemical recurrence
Lesion-type
PSA
Prostate cancer
[18F]PSMA-1007-PET/CT
Journal
EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946
Informations de publication
Date de publication:
30 Apr 2021
30 Apr 2021
Historique:
received:
27
02
2021
accepted:
21
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
Detection of the site of recurrence using PSMA-PET/CT is important to guide treatment in patients with biochemical recurrence of prostate cancer (PCa). The aim of this study was to evaluate the positivity rate of [ We included 175 [ [
Sections du résumé
BACKGROUND
BACKGROUND
Detection of the site of recurrence using PSMA-PET/CT is important to guide treatment in patients with biochemical recurrence of prostate cancer (PCa). The aim of this study was to evaluate the positivity rate of [
RESULTS
RESULTS
We included 175 [
CONCLUSION
CONCLUSIONS
[
Identifiants
pubmed: 33929626
doi: 10.1186/s13550-021-00783-w
pii: 10.1186/s13550-021-00783-w
pmc: PMC8087750
doi:
Types de publication
Journal Article
Langues
eng
Pagination
41Références
Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):397-403
pubmed: 26563121
Oncology (Williston Park). 2019 Oct 28;33(10):
pubmed: 31661149
Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):136-146
pubmed: 31492993
Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2117-2136
pubmed: 28765998
Eur Urol Focus. 2018 Sep;4(5):686-693
pubmed: 28753806
Mol Imaging Biol. 2020 Aug;22(4):1062-1069
pubmed: 31758511
Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2055-2061
pubmed: 30027419
Eur Urol. 2018 Apr;73(4):485-487
pubmed: 29132714
Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):904-912
pubmed: 29362859
J Clin Oncol. 2018 Feb 10;36(5):446-453
pubmed: 29240541
Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1284-94
pubmed: 25975367
Eur Urol. 2015 May;67(5):852-63
pubmed: 25240974
Int J Urol. 2019 Aug;26(8):804-811
pubmed: 31083784
Radiographics. 2018 Jan-Feb;38(1):200-217
pubmed: 29320333
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1607-1608
pubmed: 28488027
J Nucl Med. 2017 May;58(5):750-755
pubmed: 28062595
Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9578-82
pubmed: 21606347
Eur Urol. 2017 Apr;71(4):630-642
pubmed: 27591931
Cancer Imaging. 2018 Nov 1;18(1):39
pubmed: 30382889
J Nucl Med. 2015 Aug;56(8):1185-90
pubmed: 26112024
J Nucl Med. 2018 Apr;59(4):632-635
pubmed: 29419475
J Nucl Med. 2020 May;61(5):729-734
pubmed: 31628219
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):197-209
pubmed: 25411132
Cancers (Basel). 2019 May 23;11(5):
pubmed: 31126071
Eur Urol. 2018 May;73(5):656-661
pubmed: 29358059
J Nucl Med. 2020 Dec;61(12):1793-1799
pubmed: 32358094
Int J Cancer. 2016 Mar 15;138(6):1388-400
pubmed: 26488767
Urol Int. 2018;100(3):251-262
pubmed: 29161715
Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1329-1334
pubmed: 29541812
Eur J Nucl Med Mol Imaging. 2020 Aug;47(9):2100-2105
pubmed: 32006061
Eur J Nucl Med Mol Imaging. 2021 Feb 19;:
pubmed: 33604691
J Nucl Med. 2019 Jun;60(6):786-793
pubmed: 30530831
J Nucl Med. 2019 Mar;60(3):362-368
pubmed: 30042163
Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1258-1268
pubmed: 28497198
Pharmaceuticals (Basel). 2017 Sep 27;10(4):
pubmed: 28953234
Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):9-15
pubmed: 31654093
J Nucl Med. 2017 Nov;58(11):1797-1804
pubmed: 28450569
J Nucl Med. 2020 Jan;61(1):51-57
pubmed: 31253741
Theranostics. 2020 May 15;10(14):6082-6094
pubmed: 32483440
J Nucl Med. 2015 May;56(5):668-74
pubmed: 25791990
Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2045-2054
pubmed: 29980832
J Nucl Med. 2017 Jan;58(1):81-84
pubmed: 27660139
Prostate Cancer Prostatic Dis. 2020 Jun;23(2):343-348
pubmed: 31780781
Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):592-602
pubmed: 31728588
Mol Clin Oncol. 2017 Feb;6(2):249-254
pubmed: 28357104
Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):486-95
pubmed: 23179945
Transl Androl Urol. 2018 Oct;7(5):831-843
pubmed: 30456186